<DOC>
	<DOCNO>NCT01316185</DOCNO>
	<brief_summary>The purpose study ass optimal dose EBP921 compare efficacy safety 2 dose regimen patient chronic HDV .</brief_summary>
	<brief_title>Proof-of-concept Study Evaluating Safety Efficacy EBP921 Delta Hepatitis ( HDV )</brief_title>
	<detailed_description>This open-label , phase 1b , proof-of-concept study ass safety efficacy EBP921 , prenylation inhibitor , subject chronically infect delta hepatitis . Subjects randomize receive one two different dos EBP921 . Dosing occur 28-days time , evidence antiviral response assess frequent measurement HDV-RNA via PCR assay . In addition , safety lab data also collect along surveillance monitoring HBV activity .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<criteria>1 . Men woman age 18 old capacity give write informed consent 2 . Patients compensate chronic HDV infection indicate presence antiHDV serum . 3 . Liver biopsy perform within oneyear study screen grade use Knodell score system . 4 . Presence HDV antigen liver tissue HDVRNA serum . 5 . Active HBV replication exclude patient . 6 . Previous therapy standard alphainterferon peginterferon exclude patient . 7 . Patients HBV therapyna√Øve previously receive HBV antiviral therapy eligible . Patients currently take HBV antiviral therapy e consider case basis . 8 . Female subject reproductive potential female partner male subject two reliable form contraception start study 60 day end EBP921 dosing . 1 . Severe neuropsychiatric disorder 2 . History clinical manifestation significant metabolic , hematological , pulmonary , ischemic heart disease , significant unstable heart disease , gastrointestinal , neurological , renal , urological , endocrine , ophthalmologic disorder include severe retinopathy , immunemediated disease 3 . Pregnant breastfeeding patient inability practice adequate contraception conduct study 4 . Underlying autoimmune/immunedeficiency disease ( e.g. , lupus , sarcoidosis , celiac disease , HIV antibody positive , AIDS ) 5 . Chronic ( &gt; 4 week duration ) diarrhea 6 . Body weight &gt; 128 kg &lt; 40 kg 7 . Uncompensated cirrhosis 8 . Absolute neutrophil count less 1500 per cubic millimeter 9 . Platelet count le 90,000 per cubic millimeter 10 . Evidence concurrent HCV infection positive serum HCVRNA 11 . Evidence hepatocellular carcinoma 12 . Active substance abuse ( alcohol , inhale injected drug ) within past 12 month 13 . Diagnosis malignancy previous five year exclude superficial dermatologic malignancy 14 . Any experimental therapy previous 6 month prior enrollment . 16 . Patients history multiple drug resistant HBV 17 . Patients receive interferon therapy reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis D</keyword>
	<keyword>HDV</keyword>
	<keyword>Hepatitis</keyword>
</DOC>